ThePatientsChannel.com Videos
Living with MDS
Drorit Merkel, MD, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel, discusses some of the issues that can arise for those living with myelodysplastic syndromes and what can be done to minimize these issues. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
Quality of Life Concerns; Living with MDS
Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, discusses the quality of life (QoL) of patients with myelodysplastic syndromes, and the factors contributing to reductions and improvements in QoL. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
Improving MDS Quality of Life
Rafael Bejar, MD, PhD, UC San Diego Moores Cancer Center, San Diego, CA, discusses the quality of life of patients with myelodysplastic syndromes and the work being done to reduce the burden of this disease. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
MDS: Future Directions
Galia Bartfeld-Stemer, MD, Ha’Emek Medical Center, Afula, Israel, outlines future directions for patients with low and high-risk myelodysplastic syndromes. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
MDS Trials: What Should Patients be Looking For?
Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, discusses the upcoming myelodysplastic syndromes (MDS) clinical trials. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
MDS: What Treatments are on the Horizon?
Rafael Bejar, MD, PhD, UC San Diego Moores Cancer Center, San Diego, CA, outlines therapies on the horizon for both high and low-risk myelodysplastic syndromes. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
An In-Depth Look at MDS
Galia Bartfeld-Stemer, MD, Ha’Emek Medical Center, Afula, Israel, gives an in-depth overview of myelodysplastic syndromes (MDS), outlining the classification, etiology, diagnosis, symptoms, and treatment of the disease. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes 2020, held in Tel Aviv, Israel.
MDS 2020 Patient Meeting
Drorit Merkel, MD, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel, discusses the annual patient meeting held by the MDS Foundation and the importance of this meeting. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
MDS Patients Must Begin the Search for a Donor As Soon As Possible
Dr Maria Teresa Voso, of the University Tor Vergata, Rome, Italy, talks about the importance of starting a donor search for patients with myelodysplastic syndromes (MDS) as soon as possible. She explains that a transplant eligible patient must be tested for a donor search as soon as their diagnosis is made. Unfortunately, transplantation is not usually suitable for older patients, but for patients up to the age of 65 to 70, the search for a donor should be started as as soon as possible as time is critical.
ManagingMDS.com Webinars
Patient/Caregiver Update: What’s New and What’s Next in the Treatment of MDS?
Download Transcript Download Audio Begin Evaluation
In this activity, developed by ManagingMDS.com in cooperation with the MDS Foundation, patients with MDS and their caregivers will hear from two key experts about a variety of topics including: personalized risk stratification, iron overload, immunotherapies, and new strategies for treating lower- and higher-risk MDS. Join Dr. Mikkael Sekeres and Dr. David Steensma as they discuss best practices for considering a patient’s individual molecular abnormalities into their diagnosis and prognosis, and as they review new treatments that may change the future of MDS treatment.
This activity is supported by educational grants from Astex Pharmaceuticals and Celgene Corporation.
